8legs: International aids vaccine initiative

Your Followed Topics

#1 out of 3

Vaccine development is active for Bundibugyo Ebola as new outbreaks raise concerns in DR Congo and Uganda.
IAVI is adapting its vaccine approach to fight Bundibugyo during the ongoing outbreak.
Moderna uses mRNA technology to target Bundibugyo Ebola as part of the response.
Oxford is developing a new vaccine platform with trials expected in two to three months.
Cepi funds early-stage research to accelerate vaccine development.
Experts warn every day counts as the outbreak grows in the region.
MSF cautions the situation is deeply alarming as cases rise quickly.
Vaccine development targets Bundibugyo, a less common Ebola species with limited vaccines.
No licensed Bundibugyo vaccine exists yet as the outbreak expands.
The outbreak in DR Congo has triggered international attention and funding.

Vote 0

#2 out of 373.0K est. views

health18h ago

Survivors in Congo recount fighting the Bundibugyo Ebola strain as the outbreak expands across eastern provinces.
Health authorities report hundreds of confirmed cases, with most in Ituri’s eastern region.
WHO and partners commit funds to accelerate development of three experimental vaccines.
Frontline workers who recovered describe monitoring patients and the moment of testing negative.
Officials emphasize rapid detection, isolation, and strict infection control as key barriers.
Uganda closes its border and monitors cases to limit cross-border spread.
GOV officials highlight vaccine development as a priority amid ongoing trials.
WHO acknowledges progress and delivers support despite security and mistrust challenges.
New Ebola treatment center opens in Bunia to improve patient care.
Experts attribute recoveries to initiating care early in dedicated health facilities.

Vote 0

#3 out of 3

Three Ebola vaccines are in development as the Bundibugyo outbreak intensifies across DRC and Uganda.
WHO warns the outbreak’s true reach may be larger than reported, prompting global alert.
IAVI, Moderna, and Oxford University are among groups rushing to develop vaccines.
Experts say it could take two to three months before human testing begins for Oxford's candidate.
Cepi funds early-stage research to support vaccine development.
Global health officials urge rapid trials and readiness for deployment if vaccines prove safe.
Suspected cases in Brazil, Italy, and Austria have prompted cautious monitoring.
Health workers are deploying protective measures as fear rises.
Authorities aim to end the outbreak within four to six months in an optimistic scenario.

Vote 0

Unlimited Access

Personalized Feed

Full Experience

By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.

Create an account and enjoy content that interests you with your personalized feed

Unlimited Access

Personalized Feed

Full Experience

By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.